DGAP-News

Press Release: 4SC announces financial results for the first nine months and the third quarter of 2014 - Seite 4

Phase II trial.

Yakult Honsha, 4SC's Japanese development partner, is swiftly pushing the
development of resminostat in Japan. In the third quarter, the company
successfully completed the Phase I part clinical trial with resminostat in
patients with advanced liver cancer (HCC). The results confirmed the safety
and good tolerability of resminostat in combination with the cancer drug
sorafenib using the planned dosage regime in Asian patients. The
subsequently started randomised Phase II part of the study will focus on
investigating the efficacy of the resminostat-sorafenib combination in
comparison to the current HCC standard of care, sorafenib monotherapy. The
study will also continue to evaluate the ZFP64 biomarker.

Furthermore, Yakult Honsha started the Phase II part of a trial in the
non-small-cell lung cancer (NSCLC) indication. This trial investigates the
epigenetic compound in combination with the established cancer drug
docetaxel versus docetaxel monotherapy in Asian patients. The completed
Phase I part confirmed the good profiles of safety and tolerability of the
resminostat docetaxel combination.

4SC-202:
4SC's second epigenetic anti-cancer compound currently in clinical
development is 4SC-202, a selective inhibitor of the epigenetic regulators
LSD1 and HDAC isoforms 1, 2 and 3.

In June 2014, 4SC had published positive initial data from 4SC-202's
clinical Phase I TOPAS trial in 24 patients with advanced haematological
tumours at the ASCO Annual Meeting in Chicago. This data had shown the
compound's safety and good tolerability as well as promising indications of
anti-tumour efficacy. One patient continues to be treated with 4SC-202. He
has participated in the study for about two years and has responded to the
treatment with a complete remission of the tumorous lesions that persists
to this day. On the strength of the positive trial results, 4SC commenced
initial negotiations with potential partners in the third quarter regarding
possible clinical development partnerships for 4SC-202.

4SC-205:
The Company's third anti-cancer compound is the oral Eg5 kinesin inhibitor
4SC-205. It has now entered the last study phase of the Phase I AEGIS
trial, where it is being intensively trialled in patients with a specific
disease condition (lung tumour/metastases). Patient recruitment was
completed successfully in the reporting quarter and completion of the study
is expected in the near future.

Discovery & Collaborative Business segment (research at 4SC Discovery GmbH)